MedTrace Logo

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

NCT04113187 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-22

No results posted yet for this study

Summary

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment. Propranolol, a beta-blocker, is a potentially useful therapeutic considering its anti-angiogenic properties. Our objective is to explore the efficacy of propranolol, three months after its introduction, on the cumulative duration of epistaxis in HHT patients.

Conditions

  • Hereditary Hemorrhagic Telangiectasia
  • Osler Weber Rendu Disease

Interventions

DRUG

Propranolol treatment

40 mg twice a day (morning and evening), per os, during three months

DRUG

Placebo

per os, twice a day (morning and evening) during three months

Sponsors & Collaborators

  • AMRO-HHT-France - Association Maladie de Rendu-Osler

    collaborator UNKNOWN

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Anne CONTIS, MD · University Hospital, Bordeaux

  • Antoine BENARD, MD, PhD · University Hospital, Bordeaux

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2022-05-19
Completion
2022-05-19

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04113187 on ClinicalTrials.gov